Floatz logo

Cytosin-Arabinosid

Acute Myeloid Leukemia With Multilineage Dysplasia

National Cancer Institute (NCI)Phase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
89/ 100

Competitive context

35 Active assets in the Acute Myeloid Leukemia With Multilineage Dysplasia cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Institut de Recherches Internationales Servier
Phase 2BB
Decitabine
National Cancer Institute (NCI)
Phase 3BB
ag-120
Institut de Recherches Internationales Servier
Phase 3BB
Fludarabine
National Cancer Institute (NCI)
Phase 3BB
Cyclophosphamide
City of Hope Medical Center
Phase 3BB

View all 49 →

Same molecule, other indications

Cytosin-Arabinosid is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →